Raloxifene

Raloxifene is a benzothiophene-derived SERM that acts as a potent estrogen receptor antagonist specifically in breast tissue. It binds ER-alpha and ER-beta in mammary tissue with high affinity, blocking estradiol-mediated cellular proliferation. In breast tissue, the raloxifene-ER complex recruits co-repressors rather than co-activators, shutting down estrogen-responsive gene transcription. This is what makes it superior to tamoxifen for gyno — it has a stronger anti-estrogenic effect at the breast. In bone tissue, it acts as an estrogen agonist, preserving bone mineral density. In the hypothalamus, it has weaker anti-estrogenic activity than tamoxifen or clomiphene, which makes it less effective for pure PCT HPTA stimulation.

Oral bioavailability is approximately 2% due to extensive first-pass glucuronidation, but clinical efficacy is well-established at standard doses. Peak plasma concentration in 0.5-6 hours. Highly protein-bound (>95%). Extensively metabolized by hepatic glucuronidation (not CYP-dependent — so no CYP2D6 metabolism concerns unlike tamoxifen). Half-life of 27-32 hours supports once-daily dosing. Enterohepatic recycling contributes to sustained plasma levels.

• ✓Most effective SERM for gynecomastia reversal — 80-90% response rate in clinical studies
• ✓More breast-tissue-selective than Nolvadex — stronger anti-estrogenic effect where it matters for gyno
• ✓Does not depend on CYP2D6 metabolism — works regardless of genetic CYP2D6 status
• ✓Preserves bone mineral density via estrogenic action in bone
• ✓Favorable lipid effects — reduces LDL cholesterol
• ✓Lower incidence of mood disturbances compared to Clomid
• ✓Can be stacked with Nolvadex or enclomiphene during PCT for users with active gyno
• ✓Minimal impact on IGF-1 levels

• ⚠Hot flashes (most common side effect)
• ⚠Leg cramps
• ⚠Slightly increased risk of venous thromboembolism (DVT/PE) — similar to tamoxifen
• ⚠Peripheral edema in some users
• ⚠Mild GI upset
• ⚠Less effective than Nolvadex or Clomid for pure PCT/HPTA recovery
• ⚠Joint stiffness
• ⚠Rare: visual disturbances

Contraindications

• 🚫Active or history of venous thromboembolism (DVT, PE)
• 🚫Concurrent warfarin use (interaction)
• 🚫Pregnancy or planned pregnancy
• 🚫Severe hepatic impairment
• 🚫Premenopausal women (in clinical use)
• 🚫History of stroke or TIA

Raloxifene is not the first-choice standalone PCT compound because it is weaker at stimulating LH/FSH compared to Nolvadex or Enclomiphene. However, it can be added to a standard PCT protocol when the user has active gynecomastia that needs reversal. Recommended combo: Nolvadex or Enclomiphene for HPTA recovery + Raloxifene 60mg/day specifically targeting gyno tissue. Run the raloxifene for 3-6 months even if PCT is only 4-6 weeks.

• 1.Raloxifene is the best pharmaceutical gyno treatment — if you have a lump forming, this is the first thing to try before considering surgery
• 2.It can reverse gyno that Nolvadex failed to address due to its stronger breast tissue selectivity
• 3.For on-cycle gyno prevention, raloxifene is arguably superior to Nolvadex because it does not lower IGF-1
• 4.Can be safely combined with an AI (Anastrozole or Aromasin) for comprehensive estrogen management
• 5.Be patient with gyno reversal — full results take 3-6 months of consistent daily dosing
• 6.The 120mg acute protocol works well for halting a sudden gyno flare mid-cycle
• 7.Not CYP2D6 dependent — a major advantage for those who are poor metabolizers and found Nolvadex ineffective
• 8.Keep running it even after switching SERMs for PCT — the gyno reversal effect requires long-term treatment

1. [1]Lawrence SE et al. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr. 2004;145(1):71-76.
2. [2]Boccardo F et al. Evaluation of tamoxifen and raloxifene in the prevention of gynecomastia and breast pain induced by bicalutamide. J Clin Oncol. 2005;23(4):808-815.
3. [3]Ettinger B et al. Reduction of vertebral fracture risk with raloxifene. JAMA. 1999;282(7):637-645.